IN THE CLAIMS

- 1. (previously presented) A method for identifying a compound capable of treating a pain or a painful disorder, comprising:
 - a) combining a compound to be tested with a polypeptide selected from the group consisting of:
 - i) a polypeptide comprising an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:2, wherein the polypeptide has sulfotransferase activity;
 - a nucleotide sequence which is at least 95% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, wherein said polypeptide has sulfotransferase activity:
 - ii) a polypeptide comprising the amino acid sequence of SEQ ID NO:2; and
 - iv) ii) a polypeptide which is encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1;

under conditions suitable for binding of the test compound to the polypeptide; and

b) detecting binding of the test compound to the polypeptide to thereby identify a compound which binds to the polypeptide,

thereby identifying a compound capable of treating a pain or a painful disorder.

2. (original) The method of claim 1, wherein the compound is selected from the group consisting of a small molecule, a peptide or an antibody.

- 3. (original) The method of claim 1, wherein the polypeptide further comprises heterologous sequences.
- 4. (currently amended) The method of claim 1, wherein the polypeptide is an isolated polypeptide, a membrane-bound form of an isolated polypeptide or <u>an intracellular a cell</u> comprising the polypeptide.
- 5. (original) The method of claim 1, wherein the disorder is a disorder associated with aberrant nociception.
 - 6. (original) The method of claim 1, wherein the disorder is pain.
- 7. (original) The method of claim 1, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of: a) a competition binding assay; b) an immunoassay; and c) a yeast two-hybrid assay.
 - 8-23. (canceled)